Molecular Modeling and Biopharmaceutical Center, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536, USA.
Molecular Modeling and Biopharmaceutical Center, USA.
Chem Biol Interact. 2018 Sep 25;293:107-114. doi: 10.1016/j.cbi.2018.08.002. Epub 2018 Aug 4.
As the most popularly abused one of opioids, heroin is actually a prodrug. In the body, heroin is hydrolyzed/activated to 6-monoacetylmorphine (6-MAM) first and then to morphine to produce its toxic and physiological effects. It has been known that heroin hydrolysis to 6-MAM and morphine is accelerated by cholinesterases, including acetylcholinesterase (AChE) and/or butyrylcholinesterase (BChE). However, there has been controversy over the specific catalytic activities and functional significance of the cholinesterases, which requires for the more careful kinetic characterization under the same experimental conditions. Here we report the kinetic characterization of AChE, BChE, and a therapeutically promising cocaine hydrolase (CocH1) for heroin and 6-MAM hydrolyses under the same experimental conditions. It has been demonstrated that AChE and BChE have similar k values (2100 and 1840 min, respectively) against heroin, but with a large difference in K (2170 and 120 μM, respectively). Both AChE and BChE can catalyze 6-MAM hydrolysis to morphine, with relatively lower catalytic efficiency compared to the heroin hydrolysis. CocH1 can also catalyze hydrolysis of heroin (k = 2150 min and K = 245 μM) and 6-MAM (k = 0.223 min and K = 292 μM), with relatively larger K values and lower catalytic efficiency compared to BChE. Notably, the K values of CocH1 against both heroin and 6-MAM are all much larger than previously reported maximum serum heroin and 6-MAM concentrations observed in heroin users, implying that the heroin use along with cocaine will not drastically affect the catalytic activity of CocH1 against cocaine in the CocH1-based enzyme therapy for cocaine abuse.
作为阿片类药物中最常被滥用的一种,海洛因实际上是一种前体药物。在体内,海洛因首先被水解/激活为 6-单乙酰吗啡(6-MAM),然后转化为吗啡,从而产生其毒性和生理作用。已知海洛因水解为 6-MAM 和吗啡是由胆碱酯酶加速的,包括乙酰胆碱酯酶(AChE)和/或丁酰胆碱酯酶(BChE)。然而,关于胆碱酯酶的具体催化活性和功能意义一直存在争议,这需要在相同的实验条件下进行更仔细的动力学特征描述。在这里,我们报告了在相同的实验条件下,AChE、BChE 和一种有治疗前景的可卡因水解酶(CocH1)对海洛因和 6-MAM 水解的动力学特征。结果表明,AChE 和 BChE 对海洛因的 k 值(分别为 2100 和 1840 min)相似,但 K 值(分别为 2170 和 120 μM)差异较大。AChE 和 BChE 都可以催化 6-MAM 水解为吗啡,与海洛因水解相比,催化效率较低。CocH1 也可以催化海洛因(k=2150 min,K=245 μM)和 6-MAM(k=0.223 min,K=292 μM)的水解,与 BChE 相比,K 值较大,催化效率较低。值得注意的是,CocH1 对海洛因和 6-MAM 的 K 值均远大于此前报道的海洛因使用者体内最大血清海洛因和 6-MAM 浓度,这意味着海洛因与可卡因一起使用不会对基于 CocH1 的可卡因滥用酶治疗中 CocH1 对可卡因的催化活性产生显著影响。